2026-10-20 10:16:40
Stone Pharma (01093) Launches Phase I Trial for SYH2083 Eye Drops in Dry Eye Disease
According to Stone Pharma (01093), the company announced today that SYH2083 eye drops, a dual-target LFA-1/RASP inhibitor, has initiated a Phase I clinical trial (SYH2083-001) for dry eye disease in China. The single-center, randomized, double-blind, placebo-controlled dose-escalation trial aims to